SEPOY.net
No Result
View All Result
Saturday, July 19, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Multiple drug targets for the treatment of influenza identified using AI program

Nicholas by Nicholas
July 1, 2023
in Health
0
Multiple drug targets for the treatment of influenza identified using AI program

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason. Poolbeg has been working with CytoReason since March 2022.

READ ALSO

Hypertensive disorders in pregnancy linked to lower breastfeeding rates

Study reveals complex patterns of burden and survival among people with digestive system cancers in China

Poolbeg’s unique disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s industry-leading AI-led platform. The analysis has led to the discovery of multiple novel drug targets for the treatment of influenza.

Identification of drug targets from this unique data-set has previously been successful as p38 MAP Kinase, inhibited by POLB 001, was identified as a driver of severe influenza but this required manual analysis that took several years. However, through the utilization of CytoReason’s cutting-edge AI technology, Poolbeg has now identified multiple novel drug targets in just 15 months. Moreover, CytoReason’s analysis independently confirmed the significance of the p38 MAP kinase pathway in influenza, providing further validation for Poolbeg’s POLB 001 programme.

The Company is actively exploring the most effective way to further develop the novel drug targets in order to generate value and looks forward to updating shareholders about the progress of this programme in due course. This marks Poolbeg’s second successful AI Programme, following the identification of potential new drug candidates for Respiratory Syncytial Virus (RSV) announced in December 2022.

Our collaboration with CytoReason has put Poolbeg at the forefront of AI drug discovery. CytoReason’s deep interrogation of the uniquely rich data derived from human challenge trials has deepened our knowledge of influenza, resulting in the identification of multiple novel influenza drug targets. There is a significant unmet need for new and better treatments for vulnerable patients with influenza and this is a major milestone in the delivery of new therapies that can improve patient outcomes and global health.”

​​​​​​​Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma

David Harel, Chief Executive Officer of CytoReason, said: “Once again, we’re pleased to see that leveraging CytoReason’s computational disease models to extract insights from Poolbeg’s unique human challenge data can optimise the target discovery process. More importantly, these impressive results would not be possible without the commitment, transparency, and reciprocity of both teams.”

Tags: Artificial IntelligenceBiopharmaceuticalInfluenzaKinase

Related Posts

Hypertensive disorders in pregnancy linked to lower breastfeeding rates
Health

Hypertensive disorders in pregnancy linked to lower breastfeeding rates

July 19, 2025
Study reveals complex patterns of burden and survival among people with digestive system cancers in China
Health

Study reveals complex patterns of burden and survival among people with digestive system cancers in China

July 18, 2025
Cuproptosis offers new hope for treating inflammatory bowel disease and colorectal cancer
Health

Cuproptosis offers new hope for treating inflammatory bowel disease and colorectal cancer

July 18, 2025
New mRNA vaccine strategy awakens immune system to fight cancer
Health

New mRNA vaccine strategy awakens immune system to fight cancer

July 18, 2025
Acorn-based coffee boosts antioxidants with minimal health risk
Health

Acorn-based coffee boosts antioxidants with minimal health risk

July 18, 2025
PAR1 protein found to boost lung fluid drainage during injury
Health

PAR1 protein found to boost lung fluid drainage during injury

July 18, 2025
Next Post
Covid deaths plummet in England, but dementia and heart disease remain a concern

Covid deaths plummet in England, but dementia and heart disease remain a concern

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Hugo Local casino Review 2025 Zero-Gooey Bonus, 275 50 free spins on money rain real money 100 percent free spins!
  • Cleopatra Along with RTP Free spins Slot Ratings
  • Ruby Chance Gambling enterprise: Endless Added bonus Revolves No deposit Needed

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net